



# Biotech Daily

Monday November 9, 2020

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: ANTISENSE UP 15%; NEXT SCIENCE DOWN 6%**
- \* **PRIME MINISTER APPOINTS CSIRO'S DR CATHY FOLEY CHIEF SCIENTIST**
- \* **ALCIDION \$9.5m SOUTH TEES HOSPITAL MANAGEMENT SYSTEM DEAL**
- \* **ASTRAZENECA LEASES 200 IMPEDIMED SOZOS FOR 2nd TRIAL**
- \* **ASX APPROVES SIMAVITA DELISTING**
- \* **PATRYS \$2.5m PLACEMENT, RIGHTS ISSUE FOR \$4.8m MORE**
- \* **TRUSCREEN TO APPLY FOR ASX DUAL LISTING, RAISE UP-TO \$1.9m**
- \* **ANTISENSE APPLIES TO DUAL LIST ON FRANKFURT EXCHANGE**
- \* **AVITA, HOUSTON METHODIST PRE-CLINICAL SKIN COLLABORATION**
- \* **IMMURON VACCINE SHOWS INFECTION IMMUNE RESPONSE, IN COWS**
- \* **NOXOPHARM VEYONDA, NIVOLUMAB CANCER STUDY**
- \* **DIMERIX: REMAP-CAP COVID-19 TRIAL PROTOCOL APPROVED FOR DMX-200**
- \* **EMYRIA, ZELIRA HOPE MARIJUANA AUTISM STUDY**
- \* **RESAPP, MEDGATE INTEGRATE RESPIRATORY DIAGNOSTIC**
- \* **HERAMED, ECARE21 TO MARKET HERACARE**
- \* **IMMUTEP GRANTED IMP701 AUSTRALIAN PATENT**
- \* **ACTINOGEN FILES XANAMEM COGNITION, MANUFACTURING PATENTS**
- \* **NEUROSCIENTIFIC REQUESTS PLACEMENT TRADING HALT**
- \* **RECCE EXTENDS 'ANTIVIRAL RESULTS' SUSPENSION**
- \* **GENETIC TECHNOLOGIES 125m DIRECTORS RIGHTS AGM**
- \* **REGAL FUNDS REDUCES, DILUTED TO 7.8% OF VISIONEERING**
- \* **SOMNOMED APPOINTS KAREN BORG DIRECTOR**

## MARKET REPORT

The Australian stock market was up 1.75 percent on Monday November 9, 2020, with the ASX200 up 108.6 points to 6,298.8 points.

Twenty-one of the Biotech Daily Top 40 stocks were up, 13 fell, five traded unchanged and one was untraded. All three Big Caps were up.

Antisense was the best, up 1.5 cents or 15 percent to 11.5 cents, with 1.1 million shares traded. Impedimed climbed 13.4 percent; Neuren was up 12.6 percent; Osprey improved 10 percent; Kazia was up 9.15 percent; Nova Eye rose 7.6 percent; Dimerix, Medical Developments and Mesoblast were up more than five percent; Avita, LBT and Telix rose more than four percent; Nanosonics, Oncosil and Universal Biosensors were up three percent or more; Compumedics and Volpara rose more than two percent; CSL, Immutep, Polynovo, Pro Medicus and Resmed were up more than one percent; with Clinuvel and Cochlear up by less than one percent.

Next Science led the falls, down seven cents or 5.8 percent to \$1.13, with 506,154 shares traded. Both Cynata and Prescient lost 3.3 percent. Amplia, Genetic Signatures, Optiscan, Paradigm, Pharmaxis, Proteomics, Starpharma and Uscom shed two percent or more; Imugene was down 1.6 percent; with Opthea down 0.9 percent.

## FEDERAL GOVERNMENT

The Prime Minister's website says that the CSIRO's chief scientist Dr Cathy Foley will replace Dr Alan Finkel as Australia's chief scientist from 2021.

The website said that Dr Finkel's tenure comes to an end in December 2020 and Dr Foley would begin in January 2021.

In the media release on his website Prime Minister Scott Morrison said: "As we recover from Covid-19 and look to rebuild a brighter future, the role of the chief scientist has never been more important".

Separately Mr Morrison said that the Government had no intention of changing its climate change policies despite US President-elect Joe Biden promising to take action on climate change.

"Dr Foley has a big task ahead to drive collaboration between industry and the science and research community, as we look to create jobs for the Covid-19 recovery and for the future," Mr Morrison said.

The Federal Minister for Industry, Science and Technology Karen Andrews thanked Dr Finkel for his service and said Dr Foley would bring "a unique mix of experience to the role".

Ms Andrews said that Dr Foley was "a strong advocate for women in science, technology, engineering and mathematics and her lived experience will make her an important role model for aspiring young scientists".

The media release said that Dr Foley was Australia's second woman chief scientist, after Prof Penny Sackett, who held the role from 2008 to 2011.

The Prime Minister's website said that Dr Foley was a fellow of the Australian Academy of Science, and the Australian Academy of Technology and Engineering and made "significant contributions in the area of physics relating to superconductors".

According to her LinkedIn page, Dr Foley holds a Bachelor of Science, a Diploma of Education and Doctor of Philosophy, all from Sydney's Macquarie University.

## ALCIDION GROUP

Alcidion says it has a five-year, \$9.5 million deal with the Middlesbrough, UK-based South Tees Hospitals National Health System (NHS) for its hospital management system.

Alcidion said the deal included \$960,000 in product implementation revenue and \$8.51 million in recurring product revenue to integrate its Miya precision to digitize patient care and records and its Better Openep to digitize prescription and medicine administration.

The company said that South Tees Hospitals had more than 1,000 beds and provided care for more than 1.5 million people.

Alcidion said it expected to recognize \$5.48 million as revenue under the contract for the year to June 30, 2021, subject to a milestone achievement.

South Tees chief clinical information officer Dr Andrew Adair said the technology was “designed for clinicians by people who really understand clinicians”.

“Our agreement with Alcidion will allow us to accelerate our digital maturity and adopt modern technology that will have a very significant positive impact on the daily lives of the people who use it,” Dr Adair said.

“We have been determined to finalize this agreement at a time of unprecedented pressure in the NHS,” Dr Adair said.

“The systems we are about to implement will help to lighten the burden faced by clinical staff who are working fantastically hard, by reducing time spent on manual processes and providing some extremely impressive clinical decision support tools,” Dr Adair said.

Alcidion was up five cents or 40 percent to 17.5 cents with 56.7 million shares traded.

## IMPEDIMED

Impedimed says it has leased an additional 200 Sozo devices to Astrazeneca for a second 18-month, phase II clinical trial of chronic kidney disease.

In September, Impedimed said Astrazeneca would lease 175 bioimpedance spectroscopy Sozo devices for an 18-month, phase II trial for heart failure patients with chronic kidney disease (BD: Sep 30, 2020).

Today, the company said the second trial would evaluate the efficacy, safety and tolerability of a combination of Astrazeneca drugs, using the Sozo device to measure fluid volume, was expected to begin in January 2021 and generate revenue of \$2 million.

Impedimed said it would receive a monthly licence fee for the duration of the study and would retain ownership of the devices at the conclusion of both trials.

Impedimed managing-director Richard Carreon said that Astrazeneca’s “selection of Sozo for a second clinical trial that is focused on patients with chronic kidney disease provides important validation for our technology.”

“There are millions of people today living with chronic kidney disease, and we look forward to learning more about the impact this trial will have on improving patient care,” Mr Carreon said.

Impedimed was up 1.1 cents or 13.4 percent to 9.3 cents with 23.4 million shares traded.

## SIMAVITA

Simavita says it has formal approval from the ASX to delist, subject to shareholder approval at a December 2, 2020 meeting.

The meeting will be held at K&L Gates Level 31, 1 O’Connell Street Sydney on December 2, 2020 at 11am (AEDT).

Simavita fell 0.2 cents or 11.1 percent to 1.6 cents with 2.3 million shares traded.

## PATRY'S

Patrys says it has commitments to raise \$2.5 million in a placement and hopes to raise \$4.8 million in a non-renounceable, one-for-six rights issue at 2.0 cents.

Patrys said the 2.0 cents issue price was a 4.8 percent discount to the most recent closing price and a 15.7 percent discount to the 15-day volume weighted average price.

The company said that one option would be issued for every three new shares, exercisable at 4.0 cents within three years.

Patrys said the rights issue record date would be November 12, the offer would open on November 17 and close on December 8, 2020 and was fully-underwritten by Lazarus Corporate Finance.

The company said the funds would be used for its PAT-DX1 trial by July 2022, to expand business development activities, develop its deoxymab platform, initiate an antibody drug conjugate program and for working capital, business development and corporate activities. Patrys said it would pay a six percent placement fee to Territory Funds Management. Patrys was unchanged at 2.1 cents with 11.9 million shares traded.

## TRUSCREEN (FORMERLY POLARTECHNICS)

Truscreen says it hopes to raise \$NZ1 million (\$A934,530) to \$NZ2 million to dual-list on the ASX for its cervical cancer test and would apply to the ASX "shortly".

Truscreen said it hoped the offer at seven New Zealand cents a share (6.5 cents) would open on November 26 and close on December 18, 2020

The company said the funds would be invested in team capabilities for business expansion, establish device manufacturing in China for Chinese operations, reduce the cost of the product through research and development, market development through market access/medical affairs capability costs of the listing and working capital.

Truscreen said 14,285,714 shares worth \$NZ1 million had been set aside for subscription by Australian residents with 7,142,857 shares worth NZ\$500,000 set aside New Zealand residents.

The company said that in the event that one geographic pool was undersubscribed, the balance might be allocated to the other, and the board had the discretion to accept oversubscriptions up-to \$NZ500,000.

Last year, Truscreen's then chief executive officer Martin Dillon said the new, improved version of the company's cervical cancer test could be a primary screening tool.

In Melbourne with chairman Tony Ho and chief financial officer Guy Robertson, Mr Dillon told Biotech Daily that in the decade since Polartechinics failed to commercialize the original Truscreen diagnostic, the New Zealand-based company had redeveloped it to be wireless, portable and able to connect to all smart mobile telephones and computer systems, providing immediate, single-visit diagnosis (BD: Mat 19, 2019).

In 2008, Mr Dillon's brother, Ben Dillon, was the chief executive officer of Polartechinics and the company had announced increasing sales, but by 2010 it was in the hands of receivers, having failed to raise funds and merge with another cancer diagnostic company Fermiscan (BD: Aug 14, Dec 10, 2008; Jul 16, 2009; Feb 11, 2010).

Mr Ho said last year that the company expected to list on the ASX in August or September 2019 with an initial public offer to raise \$5 million to \$8 million to expand the commercialization of the diagnostic.

On the NZX, Truscreen closed down 0.4 NZ cents or 4.5 percent at 8.5 NZ cents (7.9 Australian cents) with 832,542 shares traded.

### ANTISENSE THERAPEUTICS

Antisense says it has begun proceedings to apply for a dual listing on the Frankfurt Stock Exchange to facilitate European investment.

Antisense said that the Frankfurt-based Institute for Asset and Equity Allocation and Valuation (Deutsche Gesellschaft für Wertpapieranalyse GmbH or DGWA) had been appointed its European investor and corporate relations advisor.

The company said DGWA would engage retail, institutional and family office investors in Germany, Austria and Switzerland for the company.

Antisense chief executive officer Mark Diamond said the move onto the Frankfurt exchange “strongly aligns with our clinical development plans for ATL1102 in Europe and the expectation of strong investor and corporate interest in our program”.

Antisense was up 1.5 cents or 15 percent to 11.5 cents with 1.1 million shares traded.

### AVITA THERAPEUTICS

Avita says it has a pre-clinical research collaboration with Texas’ Houston Methodist Research Institute to pair its spray-on skin cells with the Institute’s RNA expertise.

Avita said the project aimed to establish proof-of-concept, using the Institute’s RNA-based approach to rejuvenating human cells, in order to develop an “approach to reverse aging and rejuvenate skin, with the potential for broader applicability, such as scar revision and wound healing”.

The company said it also had an option agreement to negotiate an exclusive, licence to the patented technology for skin applications and first right of negotiation for emerging technologies from the collaboration.

Avita said it would have access to the Institute’s technologies, including an RNA-based approach to rejuvenate human cells and proof-of-concept that their RNA technology reversed the aging of cells, and it expected the initial research program to take 18 months.

Avita was up 27 cents or 4.55 percent to \$6.21 with 309,939 shares traded.

### IMMURON

Immuron says that the US Naval Medical Research Center has found that a colostrum vaccine has an immunological response to bacterial infections in cows.

Immuron said that it had completed characterization of the colostrum, harvested from cows immunized with an experimental vaccine for Campylobacter and Enterotoxigenic Escherichia coli (ETEC), which found that it produced an immune response.

The company said the vaccine contained high levels of antibodies that specifically targeted Campylobacter jejuni and ETEC colonization factor antigen 1, which predicted that it would be protective against diarrhoea induced by both infections.

Immuron said that the US Department of Defence’s Naval Medical Research Center (NMRC) had found that the colostrum contained high levels of immunoglobulins against the target antigens in the vaccine and contained antibodies that could inhibit the ETEC strain that would be used in a planned human trial.

The company said it also had a research agreement with PCI Clinical Services to manufacture the product, which would be evaluated by the US Department of Defence this month and completed by the end of 2020.

Immuron said that the NMRC planned to file an investigational new drug application with the US Food and Drug Administration by April 2021 and the vaccine would be assessed in two phase II inpatient trials of up-to 60-patients in 2021.

Immuron was up 5.75 cents or 25.3 percent to 28.5 cents with 6.6 million shares traded.

### NOXOPHARM

Noxopharm says it will conduct a 30-patient, pilot study of Veyonda in combination with Bristol Myers Squibb's nivolumab for breast, ovarian, prostate and sarcoma cancers. Noxopharm said the investigator-initiated study, conducted with principal investigator Prof Paul De Souza at three Sydney hospitals, would assess whether Veyonda, or NOX66, was able to overcome an inherent resistance to immune checkpoint inhibitors in some patients.

The company said the research had pointed to a lack of competent immune function in cancer as a limiting factor, but Veyonda had been shown to restore immune function. Noxopharm said it expected to recruit the first patients in 2021 following ethics approvals. Noxopharm was up 3.5 cents or seven percent to 53.5 cents.

### DIMERIX

Dimerix says the domain protocol for its DMX-200 to join the existing Remap-cap trial for Covid-19 acute respiratory distress syndrome (Ards) has been published.

Dimerix said the randomized, open-label study would enrol hospital patients Covid-19 Ards and aimed to assess the efficacy, in-hospital mortality and the number of days on a respirator following treatment with DMX-200 in combination with an angiotensin receptor blocker for up to 10 days.

The company said that the study was designed so that it could be rapidly extended into additional trial sites if positive data was found.

Dimerix said DMX-200 aimed to reduce damage from inflammatory immune cells by blocking signalling and limiting subsequent movement in the lungs or other tissues damaged by the virus.

The company said it would submit an investigational new drug application or equivalent in selected countries with sites recruiting patients including in Europe, the UK and Canada.

Dimerix said the protocol was at <https://www.remapcap.org/protocol-documents>.

Dimerix was up 1.5 cents or 5.7 percent to 28 cents with 1.2 million shares traded.

### ZELIRA THERAPEUTICS, EMYRIA (FORMERLY EMERALD CLINICS)

Emyria and Zelira say they have a real-world data agreement for an up to 150-patient observational trial of Zelira's Hope marijuana for autism spectrum disorder.

In September, Emyria and Zelira said that they had an initial 12-month agreement for an up-to 100-patient study of Zelira's Zenivol for chronic insomnia using Emyria's network of clinics (BD: Sep 30, 2020).

Today, the companies said that Zelira would pay Emyria \$115,000 in fees in two installments for the first six months of the 12-month agreement, as well as a subscription fee for each patient enrolled.

Emyria and Zelira said that Emyria would provide real-world longitudinal data from autism patients prescribed with Hope products, including efficacy and safety data of co-morbidities, concomitant medications, dosing information and patient responses.

The companies said Emyria's network of clinics would provide patient access and the study design would facilitate strategic engagement with key autism community stakeholders.

Emyria was up 0.9 cents or 12.7 percent to eight cents.



Zelira was unchanged at 7.2 cents with 3.8 million shares traded.

#### RESAPP HEALTH

Resapp says it has a six-month joint development and pilot agreement with Switzerland's Medgate to integrate its smartphone acute respiratory diagnostic test Resappdx.

Resapp said Medgate provided telemedicine services and the integration was expected to take two months, with a three-month pilot period to evaluate the integration expected to begin in early 2021 and it expected to enter negotiations of the cost model during the pilot program and would not receive material revenue from the pilot project.

Resapp was up half a cent or 5.8 percent to 9.1 cents with 4.1 million shares traded.

#### HERAMED

Heramed says it has an initial three-year agreement with the Orlando, Florida-based Ecare21 to integrate its Heracare platform and Herabeat foetal monitor into Ecare21.

In September, Heramed said it had partnered with Ecare21 to integrate Heracare and Herabeat into the Ecare21 platform (BD: Sep 16, 2020).

Today, the company said Heracare would be marketed and delivered by both companies to Ecare21's healthcare provider base, with providers paying an upfront establishment fee and a monthly per user subscription fee on similar commercial terms as direct sales.

Heramed fell one cent or 7.4 percent to 12.5 cents.

#### IMMUTEP

Immutep says it has been granted an Australian patent for LAG525, the humanised form of its IMP701 antibody for cancer or infectious diseases.

Immutep said the patent, titled 'Antibody molecules to LAG-3 and uses thereof' would protect its intellectual property until March 13, 2035.

Immutep was up half a cent or 1.7 percent to 29.5 cents with 2.8 million shares traded.

#### ACTINOGEN MEDICAL

Actinogen says it has filed two patents with Australia IP (intellectual property) for a method to improve cognitive decline and the manufacturing of Xanamem.

Actinogen said a patent, titled 'Medicinal Cognitive Treatments', and a provisional patent, titled 'Process for preparing Heterocyclic methanone compounds and AZA-Bicyclo intermediates thereof', would protect its intellectual property until 2040.

Actinogen was unchanged at 2.2 cents with 7.5 million shares traded.

#### NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific has requested a trading halt pending "an announcement to the market in relation to a share placement to international strategic investors".

Trading will resume on November 13, 2020 or on an earlier announcement.

Neuroscientific last traded at 30 cents.

#### RECCE PHARMACEUTICALS

Recce has requested an extension to the voluntary suspension following a trading halt for an "announcement relating to anti-viral testing results" (BD: Nov 3, 5, 2020).

Trading will resume on November 10, 2020 or on an earlier announcement.

Recce last traded at 95 cents.

### [GENETIC TECHNOLOGIES](#)

Genetic Technologies says investors will vote to issue 125,000,000 performance rights to directors and 195,975,000 warrants (American options) to HC Wainwright & Co.

Genetic Technologies said its annual general meeting would vote to issue 57,500,000 performance rights each to interim chief executive officer and director Dr George Muchnicki and chair Peter Rubinstein and 5,000,000 performance rights each to non-executive directors Nick Burrows and Lindsay Wakefield as incentives.

The company said the 5,000,000 class A performance rights to Mr Burrows and Mr Wakefield and 7,500,000 class A rights to Dr Muchnicki and Mr Rubinstein would vest when the share price reached 1.2 cents or greater for a consecutive 10-day period.

Genetic Technologies said the 25,000,000 class B rights each to Dr Muchnicki and Mr Rubinstein would vest on a 1.4 cent 10-day share price and the 25,000,000 class C performance rights each would vest on a minimum 4,000 tests processed in 12 months.

Genetic Technologies said it would vote to issue the warrants to HC Wainwright & Co as its exclusive placement agent no later than three months from the meeting.

The company said the options would remain unlisted, with 156,000,000 exercisable at 0.42 cents and 39,975,000 exercisable at 1.0 cent a share within five years.

Genetic Technologies said it would also vote to adopt its remuneration report, re-elect Mr Wakefield as a director, ratify the prior issue of options and shares and approve a 10 percent placement capacity.

The virtual meeting will be held on December 10, 2020 at 9am (AEDT) and investors can register by email at: [info@gtglabs.com](mailto:info@gtglabs.com).

Genetic Technologies fell 0.05 cents or 6.7 percent to 0.7 cents with 3.7 million shares traded.

### [VISIONEERING TECHNOLOGIES](#)

Regal Funds Management says it has reduced its substantial shareholding in Visioneering from 83,018,688 shares (8.87%) to 77,487,914 shares (7.80%).

The Sydney-based Regal Funds said that on September 21 and October 19, 2020 it sold 8,730,774 shares for \$214,392 or 2.5 cents a share and it was diluted on November 2, 2020 in the exercise of 9,464,281 unlisted options.

Visioneering was up 0.1 cents or 3.3 percent to 3.1 cents with 1.7 million shares traded.

### [SOMNOMED](#)

Somnomed says it has appointed Karen Borg as a non-executive director, effective from November 26, 2020.

Somnomed said Ms Borg was previously Healthdirect Australia chief executive officer, jobs for New South Wales chief executive officer and was Resmed's Asia Pacific and Middle East president, Johnson & Johnson vice-president and previously worked for Revlon, Seagram, Goodman Fielder and Nestle.

Somnomed said Ms Borg held a Bachelor of Arts from the University of Sydney.

Somnomed was up 19 cents or 10.05 percent to \$2.08.



email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au); twitter: @biotech\_daily